The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug ...

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is ...

Feb. 21, the Food and Drug Administration said there is no longer a short supply of the weight loss and diabetes drugs Wegovy ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

High-end brands are churning through creative directors as they try to revive sales.

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment. Never before was there a drug that actually worked for weight loss.

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease. Kroger is cutting about 200 employees ...

The company’s GLP-1 drugs, Ozempic and Wegovy, drove significant revenue growth, accounting for 61% of total sales, despite some market challenges. Insulin sales also outperformed. Novo’s next ...